Exact Sciences and Mayo Clinic Extend, Expand Collaboration to Continue Fighting Cancer through Advanced Screening

Unique Arrangement Aims to Build on the Success of Cologuard®

MADISON, Wis. -- Exact Sciences Corp. (NASDAQ: EXAS) and Mayo Clinic today announced a five-year extension and expansion of their collaboration, broadening their efforts to develop screening, surveillance and diagnostic tests beyond colorectal cancer to address other diseases within the gastrointestinal tract.

Read More

Topics: Exact Sciences News

Exact Sciences Announces Norton Healthcare to Adopt Cologuard

First and only FDA-approved noninvasive stool DNA screening test for colorectal cancer

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) today announced Norton Healthcare is the first healthcare system in Kentucky to offer Cologuard®, the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. Cologuard makes it easy for average risk patients 50 years and older to get screened at their convenience and in the privacy and comfort of their own home without having to worry about taking time off work to prepare for an invasive procedure.

Read More

Topics: Investor Relations

Exact Sciences Announces Cologuard Will Now Be Available By Prescription Through MDVIP Physicians

BOCA RATON, Fla. & MADISON, Wis.--(BUSINESS WIRE)-- MDVIP, the leader in personalized preventive medicine with a nationwide network of over 750 affiliated primary care physicians, announced today that Cologuard®, the first and only Food and Drug Administration (FDA) approved, noninvasive stool DNA screening test for colorectal cancer will now be available by prescription through its physicians. MDVIP is the first personalized healthcare network to partner with Exact Sciences to bring this innovative new test to its primary care physicians.

"MDVIP physicians have traditionally been early adopters of medical innovation," says Dr. Andrea Klemes, Chief Medical Officer of MDVIP. "Cologuard, a significant advancement in colorectal cancer detection, will allow our patients who are 50 years and older and at average risk for colorectal cancer, an easy to use screening test which they can do in the privacy of their own home."

Read More

Topics: Exact Sciences News